Infect Immun. 1993 July; 61(7): 2966-2972
Effects of strain variation, serotype, and structural modification on kinetics for activation and binding of C3 to Cryptococcus neoformans.
B J Young and
T R Kozel
Department of Microbiology, University of Nevada, Reno 89557.
ABSTRACT
Incubation of encapsulated cells of Cryptococcus neoformans in normal human serum leads to activation of the alternative complement pathway and deposition of opsonic fragments of C3 into the capsule. We determined whether the variation in capsular structure that occurs among the four major cryptococcal serotypes was reflected in the kinetics for activation and binding of C3. We also examined the effects on activation kinetics of de-O-acetylation or periodate oxidation of the capsule. Binding kinetics were characterized in terms of the time required to deposit 5% of the maximal amount of C3 on the yeast (t5%), the first-order rate constant for amplification of C3 deposition (k'), and the maximum amount of C3 that could be deposited in the capsule (C3max). Our results showed that variations in the capsular structure that characterized each serotype had no significant influence on C3max but that the rate of C3 deposition depended significantly on the serotype. C3 accumulated at a higher rate on cells of serotypes A and D than on cells of serotypes B and C. There was a significant correlation between capsular volume and C3max, although the relationship was not linear. Periodate treatment of encapsulated cryptococci of all four serotypes led to decapsulation. Periodate-oxidized encapsulated cells displayed kinetics for activation and binding of C3 that were identical to kinetics observed with nonencapsulated cryptococci. Finally, de-O-acetylation led to a significant but relatively minor increase in C3max.
Infect Immun. 1993 July; 61(7): 2966-2972
This article has been cited by other articles:
-
Pirofski, L.-A.
(2006). Of Mice and Men, Revisited: New Insights into an Ancient Molecule from Studies of Complement Activation by Cryptococcus neoformans.. Infect. Immun.
74: 3079-3084
[Full Text]
-
Ellerbroek, P. M., Lefeber, D. J., van Veghel, R., Scharringa, J., Brouwer, E., Gerwig, G. J., Janbon, G., Hoepelman, A. I. M., Coenjaerts, F. E. J.
(2004). O-Acetylation of Cryptococcal Capsular Glucuronoxylomannan Is Essential for Interference with Neutrophil Migration. J. Immunol.
173: 7513-7520
[Abstract]
[Full Text]
-
Kozel, T. R., Levitz, S. M., Dromer, F., Gates, M. A., Thorkildson, P., Janbon, G.
(2003). Antigenic and Biological Characteristics of Mutant Strains of Cryptococcus neoformans Lacking Capsular O Acetylation or Xylosyl Side Chains. Infect. Immun.
71: 2868-2875
[Abstract]
[Full Text]
-
Monari, C., Kozel, T. R., Bistoni, F., Vecchiarelli, A.
(2002). Modulation of C5aR Expression on Human Neutrophils by Encapsulated and Acapsular Cryptococcus neoformans. Infect. Immun.
70: 3363-3370
[Abstract]
[Full Text]
-
Pangburn, M. K., Pangburn, K. L. W., Koistinen, V., Meri, S., Sharma, A. K.
(2000). Molecular Mechanisms of Target Recognition in an Innate Immune System: Interactions Among Factor H, C3b, and Target in the Alternative Pathway of Human Complement ,2. J. Immunol.
164: 4742-4751
[Abstract]
[Full Text]
-
MacGill, T. C., MacGill, R. S., Casadevall, A., Kozel, T. R.
(2000). Biological Correlates of Capsular (Quellung) Reactions of Cryptococcus neoformans. J. Immunol.
164: 4835-4842
[Abstract]
[Full Text]
-
Syme, R. M., Bruno, T. F., Kozel, T. R., Mody, C. H.
(1999). The Capsule of Cryptococcus neoformans Reduces T-Lymphocyte Proliferation by Reducing Phagocytosis, Which Can Be Restored with Anticapsular Antibody. Infect. Immun.
67: 4620-4627
[Abstract]
[Full Text]
-
Cleare, W., Cherniak, R., Casadevall, A.
(1999). In Vitro and In Vivo Stability a Cryptococcus neoformans Glucuronoxylomannan Epitope That Elicits Protective Antibodies. Infect. Immun.
67: 3096-3107
[Abstract]
[Full Text]
-
Vecchiarelli, A., Retini, C., Casadevall, A., Monari, C., Pietrella, D., Kozel, T. R.
(1998). Involvement of C3a and C5a in Interleukin-8 Secretion by Human Polymorphonuclear Cells in Response to Capsular Material of Cryptococcus neoformans. Infect. Immun.
66: 4324-4330
[Abstract]
[Full Text]
-
Casadevall, A., Cleare, W., Feldmesser, M., Glatman-Freedman, A., Goldman, D. L., Kozel, T. R., Lendvai, N., Mukherjee, J., Pirofski, L.-a., Rivera, J., Rosas, A. L., Scharff, M. D., Valadon, P., Westin, K., Zhong, Z.
(1998). Characterization of a Murine Monoclonal Antibody to Cryptococcus neoformans Polysaccharide That Is a Candidate for Human Therapeutic Studies. Antimicrob. Agents Chemother.
42: 1437-1446
[Abstract]
[Full Text]
-
Kozel, T. R., deJong, B. C. H., Grinsell, M. M., MacGill, R. S., Wall, K. K.
(1998). Characterization of Anticapsular Monoclonal Antibodies That Regulate Activation of the Complement System by the Cryptococcus neoformans Capsule. Infect. Immun.
66: 1538-1546
[Abstract]
[Full Text]
-
Kozel, T. R., MacGill, R. S., Wall, K. K.
(1998). Bivalency Is Required for Anticapsular Monoclonal Antibodies To Optimally Suppress Activation of the Alternative Complement Pathway by the Cryptococcus neoformans Capsule. Infect. Immun.
66: 1547-1553
[Abstract]
[Full Text]
Copyright © 1993 by the American Society for Microbiology. All rights reserved.